Tassos Gianakakos
Chief Executive Officer presso MYOKARDIA, INC.
Patrimonio netto: 117 331 $ in data 31/03/2024
Profilo
Attualmente, Anastasios E. Gianakakos ricopre la posizione di amministratore delegato di MyoKardia, Inc. È anche nel consiglio di amministrazione di LianBio. In passato il signor Gianakakos è stato presidente e vicepresidente senior dello sviluppo aziendale presso Codexis, Inc., ingegnere di processo presso Merck & Co., Inc., direttore dello sviluppo aziendale presso Maxygen, Inc. e amministratore delegato e vicepresidente senior presso MAP Pharmaceuticals LLC. Ha conseguito una laurea al Massachusetts Institute of Technology, una laurea alla Northwestern University e un MBA alla Harvard Business School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
LIANBIO
0.35% | 15/02/2024 | 363 253 ( 0.35% ) | 117 331 $ | 31/03/2024 |
Posizioni attive di Tassos Gianakakos
| Società | Posizione | Inizio |
|---|---|---|
| MYOKARDIA, INC. | Chief Executive Officer | 01/10/2013 |
| LIANBIO | Director/Board Member | 01/08/2020 |
Prolaio, Inc.
 Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | President | - |
Precedenti posizioni note di Tassos Gianakakos
| Società | Posizione | Fine |
|---|---|---|
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Corporate Officer/Principal | 01/03/2013 |
| MERCK & CO., INC. | Chief Tech/Sci/R&D Officer | 01/01/1997 |
| CODEXIS, INC. | President | - |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
Formazione di Tassos Gianakakos
| Massachusetts Institute of Technology | Undergraduate Degree |
| Northwestern University | Graduate Degree |
| Harvard Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| CODEXIS, INC. | Process Industries |
| LIANBIO | Health Technology |
| Aziende private | 4 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Health Technology |
- Borsa valori
- Insiders
- Tassos Gianakakos
